Restricted accessResearch articleFirst published online 2018-05
Second-Generation Antipsychotics in Adolescent Psychiatric Patients: Metabolic Effects and Impact of an Early Weight Change to Predict Longer Term Weight Gain
To examine the metabolic profile of adolescents at baseline and to determine the potential predictive power of a 1-month weight gain (WG) on weight changes during longer term second-generation antipsychotic (SGA) treatment.
Methods:
A retrospective chart review study, including patients between 13 and 18 years of age and treated with SGA, was conducted. Available data at baseline, 1, 3, and 12 months of treatment were recorded.
Results:
Four hundred fifty-six patients were included, with a median age of 15 years. Ten percent of the patients were obese (>95th percentile) and abdominal obesity (>90th percentile) was observed in 12% of patients. In a subgroup of 42 patients with both baseline, 1, and 3-month weight data available, WG >4.5% after 1 month was found to be the best predictor (sensitivity: 100; specificity: 66; area under the curve: 83) for a WG >15% after 3 months. After adjusting for potential confounders, a threshold of WG >4% was found as being the best predictor.
Conclusions:
A worrisome prevalence of metabolic disorders was observed in an adolescent psychiatric cohort. In such patients, a WG >4% during the first month of treatment should raise concerns about weight controlling strategies. Further research is needed to confirm the present results and to determine the impact of a 1-month WG on a 1-year weight change.
Get full access to this article
View all access options for this article.
References
1.
BirmaherB, RyanND, WilliamsonDE, BrentDA, KaufmanJ, DahlRE, PerelJ, NelsonB: Childhood and adolescent depression: A review of the past 10 years. Part I. J Am Acad Child Adolesc Psychiatry, 35:1427–1439, 1996.
2.
BlockWM, PutzerGJ, JaramilloJR: Children with type 2 diabetes mellitus and the prevalence of psychiatric disorders. South Med J, 103:1214–1218, 2010.
3.
ChoongE, SolidaA, LechaireC, ConusP, EapCB: Suivi du syndrome métabolique induit par les antipsychotiques atypiques: Recomendations et perspectives pharmacogénétiques. Rev Med Suisse, 4:1994–1999, 2008.
4.
CitromeL, VreelandB: Schizophrenia, obesity, and antipsychotic medications: What can we do?. Postgrad Med, 120:18–33, 2008.
5.
CohenD, BonnotO, BodeauN, ConsoliA, LaurentC: Adverse effects of second-generation antipsychotics in children and adolescents: A Bayesian meta-analysis. J Clin Psychopharmacol, 32:309–316, 2012.
6.
Compendium Suisse des Medicaments. Bern, Switzerland, Institut Suisse des produits thérapeutiques, 2015.
7.
CorrellCU, ManuP, OlshanskiyV, NapolitanoB, KaneJM, MalhotraAK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA, 302:1765–1773, 2009.
8.
De HertM, DekkerJM, WoodD, KahlKG, HoltRI, MollerHJ: Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry, 24:412–424, 2009.
9.
De HertM, DetrauxJ, van WinkelR, YuW, CorrellCU: Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol, 8:114–126, 2012.
10.
De HertM, DobbelaereM, SheridanEM, CohenD, CorrellCU: Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry, 26:144–158, 2011.
11.
de HoogdS, OverbeekWA, HeerdinkER, CorrellCU, de GraeffER, StaalWG: Differences in body mass index z-scores and weight status in a Dutch pediatric psychiatric population with and without use of second-generation antipsychotics. J Child Adolesc Psychopharmacol, 22:166–173, 2012.
12.
FraguasD, Merchan-NaranjoJ, LaitaP, ParelladaM, MorenoD, Ruiz-SanchoA, CifuentesA, GiraldezM, ArangoC: Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry, 69:1166–1175, 2008.
13.
HagmanE, ReinehrT, KowalskiJ, EkbomA, MarcusC, HollRW: Impaired fasting glucose prevalence in two nationwide cohorts of obese children and adolescents. Int J Obes (Lond), 38:40–45, 2014.
14.
HoffmannVP, CaseM, StaufferVL, JacobsonJG, ConleyRR: Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials. J Clin Psychopharmacol, 30:656–660, 2010.
15.
Huber-GisekeT, PerinM, NarringF: Quelle surveillance médicale des adolescents sous antipsychotiques de deuxième génération. Rev Med Suisse, 10:1302–1307, 2014.
16.
KempDE, CorrellCU, TohenM, DelbelloMP, GanocySJ, FindlingRL, ChangK: Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia. J Child Adolesc Psychopharmacol, 23:522–530, 2013.
17.
LeuchtS, CiprianiA, SpineliL, MavridisD, OreyD, RichterF, SamaraM, BarbuiC, EngelRR, GeddesJR, KisslingW, StapfMP, LassigB, SalantiG, DavisJM: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet, 382:951–962, 2013.
18.
LipkovichI, CitromeL, PerlisR, DeberdtW, HoustonJP, AhlJ, HardyT: Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol, 26:316–320, 2006.
19.
LipkovichI, JacobsonJG, HardyTA, HoffmannVP: Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. BMC Psychiatry, 8:78, 2008.
20.
O'DonoghueB, SchaferMR, BeckerJ, PapageorgiouK, AmmingerGP: Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics. Early Interv Psychiatry, 8:276–280, 2014.
21.
PanagiotopoulosC, RonsleyR, DavidsonJ: Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications. Can J Psychiatry, 54:743–749, 2009.
22.
PinheiroJ, BatesD, DebRoyS, SarkarD, TeamRC: nlme: Linear and Nonlinear Mixed Effects Models. R package version 3., 1-108. 2013.
23.
PringsheimT, PanagiotopoulosC, DavidsonJ, HoJ, for the CAMESA Guideline Group: Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. Paediatr Child Health, 16:581–589, 2011.
24.
RatzoniG, GothelfD, Brand-GothelfA, ReidmanJ, KikinzonL, GalG, PhillipM, ApterA, WeizmanR: Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study. J Am Acad Child Adolesc Psychiatry, 41:337–343, 2002.
25.
RettewDC, GreenblattJ, KamonJ, NealD, HarderV, WassermanR, BerryP, MacLeanCD, HogueN, McMainsW: Antipsychotic medication prescribing in children enrolled in Medicaid. Pediatrics, 135:658–665, 2015.
26.
RingenPA, EnghJA, BirkenaesAB, DiesetI, AndreassenOA: Increased mortality in schizophrenia due to cardiovascular disease—a non-systematic review of epidemiology, possible causes, and interventions. Front Psychiatry, 5:137, 2014.
27.
RobinX, TurckN, HainardA, TibertiN, LisacekF, SanchezJC, MullerM: pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics, 12:77, 2011.
28.
RomualdoMC, de NobregaFJ, EscrivaoMA: Insulin resistance in obese children and adolescents. J Pediatr (Rio J), 90:600–607, 2014.
29.
RoyG, BedardA, DesmaraisPA, JourdainF, AllenS, MichaudD, Ben AmorL: Age-dependent metabolic effects of second-generation antipsychotics in second-generation antipsychotic-naive French Canadian patients. J Child Adolesc Psychopharmacol, 20:479–487, 2010.
30.
SaferDJ: A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol, 24:429–436, 2004.
31.
SweetingHN: Gendered dimensions of obesity in childhood and adolescence. Nutr J, 7:1, 2008.
32.
Swiss Health Survey 2012. Neuchâtel, Switzerland, Swiss Federal Statistical Office, 2013.
33.
SzymanskiS, LiebermanJA, AlvirJM, MayerhoffD, LoebelA, GeislerS, ChakosM, KoreenA, JodyD, KaneJ, WoernerM, CooperT: Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry, 152:698–703, 1995.
34.
U.S. Department of Health & Human Services. Clinical Growth Charts. Centers for Disease Control, 2009.
35.
VandenbergheF, Gholam-RezaeeM, Saigí-MorguiN, DelacrétazA, ChoongE, Solida-TozziA, KollyS, ThonneyJ, FassassiS, AhmedH, AmbresinA, von GuntenA, ConusP, EapCB: Importance of early weight gain changes to predict long term weight gain during psychotropic drug treatment. J Clin Psychiatry, 76:e1417–e1423, 2015.
36.
VitielloB, CorrellC, Van Zwieten-BootB, ZuddasA, ParelladaM, ArangoA: Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol, 19:629–635, 2009.
37.
WinterfeldU, Le HeuzeyMF, AcquavivaE, MourenMC, BrionF, BourdonO: Psychotropic medication use in the child and adolescent psychiatry wards of a French hospital. Pharm World Sci, 30:600–604, 2008.
38.
ZimmetP, AlbertiKG, KaufmanF, TajimaN, SilinkM, ArslanianS, WongG, BennettP, ShawJ, CaprioS, Group IDFC: The metabolic syndrome in children and adolescents—an IDF consensus report. Pediatric diabetes, 8:299–306, 2007.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
